Skip to main content
OpenTrials
Completed

NCT Number: NCT05454098

Clifutinib Food Effect Study in Healthy Subjects

The purpose of this study is to evaluate to determine the effect of food on the PK of a single dose of 40 mg Clifutinib in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

the First Hospital of Jilin University

Changchun, Jilin, 130021, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects (male or female), age greater than or equal to 18 years and less than or equal to 45 years;
  • Weight ≥50 kg (≥45 kg for female), and have a body mass index (BMI) between 18 and 28 (including 18 and 28) at screening;
  • Physical examination, clinical laboratory examination and other related examinations are normal or acceptable deviations that are judged to be not clinically significant by the investigator;
  • Male or female subjects with child-bearing potential must agree to use effective contraception during the study and within 6 months after the administration of the last dose, and sperm donation is not allowed for male subjects during the study; female subjects must be non-pregnant and non-lactating;
  • Volunteer to participate in this study, understand the study procedures and sign the informed consent prior to any study specific procedures, good compliance and willing to follow study procedures.

Exclusion criteria

  • Have a history of or current cardiovascular, respiratory, hematological, hepatic, renal, gastrointestinal, endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs;
  • Unable to tolerate standard meals;
  • Prolonged QT interval corrected for heart rate using Fridericia's formula (QTcF) >470 ms (female >480 ms), or history of long QT syndrome;
  • Have received live vaccine(s) within 3 months prior to screening;
  • Have used over-the-counter or prescription medication , including herbal medications, within 14 days prior to dosing and during the study;
  • Have known allergy to any drug or food;
  • Smoking more than 5 cigarettes per day (or equivalent in tobacco or nicotine products) within 3 months prior to screening, or unwilling to abide by smoking restrictions during the study;
  • Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody ,human immunodeficiency virus (HIV) antibody or Treponema pallidum antibody;
  • Known history of drug abuse

Treatment and study plan

Clifutinib with fed state

Drug

40 mg Clifutinib with food

Clifutinib with fasted state

Drug

40 mg Clifutinib without food

Primary outcomes

  1. Cmax

    Time frame: 4 weeks

    Pharmacokinetics parameters in fasting state and fed state

  2. AUC0-∞

    Time frame: 4 weeks

    Pharmacokinetics parameters in fasting state and fed state

Secondary outcomes

  1. Adverse Events

    Time frame: Through study completion, an average of 4 weeks

    Safety and tolerability measure by number of subjects who experience adverse events

Sponsors and collaborators

Lead sponsor

Sunshine Lake Pharma Co., Ltd.

Industry

Registry information

Official study title

A Food Effect Phase I Study of the Clifutinib in Healthy Subjects

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jul 12, 2022
Registry last updated
Mar 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.